Liver Transplantation in Egypt

Mai I Mehrez*
National Hepatology and Tropical Medicine Research Institute, Egypt

*Corresponding author: Mai I Mehrez, Fellow of Hepatology, National Hepatology and Tropical Medicine Research Institute, Egypt, Email: maymehrezmd@yahoo.com

Submission: July 31, 2017; Published: November 13, 2017

Abstract
Liver transplantation is the best solution for patients suffering from end stage liver disease. The magnitude of liver disease in Egypt is remarkable due to HCV infection. The pool of donors does not cover the increasing need for this modality. Deceased program although it has been approved legally since 2010 but still not activated and the detailed regulations are not yet established due to resistance of some groups as religious and human rights. In this review, we show the progress of liver transplantation in Egypt since its start in 1991 and aiming to start the deceased program soon.

Introduction
Liver transplantation (LT) is currently the treatment of choice for patients with advanced chronic liver failure for which no other therapy is available [1]. In Egypt, there is no doubt that chronic liver diseases are a major health concern. Hepatitis C virus (HCV) prevalence among the 15-59 years age group is estimated to be 14.7%. Accordingly, Egypt has the highest HCV prevalence in the world. Today, HCV infection and its complications are among the leading public health challenges in Egypt [2].

In Egypt, the use of deceased organ donors is still prohibited, and as a result, some patients seek liver transplant abroad. Thus living donor liver transplant is the only possible option for patients with end stage liver disease in Egypt [3]. The purpose of this article is to review the evolution of LT in Egypt and the current status.

Historical Background
In July 1989, Strong et al. performed the first successful transplantation of a liver graft from a living related donor; the donor was a 29-year-old woman and the recipient was a 17-month-old son [4]. Living donor liver transplant (LDLT) was first performed in Egypt in 1991 by the surgical team at the National Liver Institute (NLI), Menoufeya University, with the help of Prof. Habib. The longest recipient survival was 11 months.

The breakthrough was made in Dar Al-Fouad Hospital by starting the program of LDLT (August 2001), with Prof. Tanaka, Kyoto University, Japan. This was followed by Wady El-Neel Hospital (October 2001), NLI, Menoufeya University (April 2003) and Maadi Armed Forces Hospital (September 2003). By that time, there was increase in number of centers doing LDLT (13 centers) and increase in number of LDLT cases (2,500) with improvement of the results of LDLT [5].

Indications
Yosry et al. showed that hepatitis C related ESLD is the main indication for liver transplantation and represents 89.9% of cases in Egypt, while HBV and other indications (cryptogenic cirrhosis, Wilson disease, and glycogen storage disease) represent 5.1% and 5.1% respectively [6] (Figure 1).

Outcome
Yosry and his colleagues showed in their study in 2008 that recipient and graft survivals were 86.6% at the end of the follow-up which was comparable to literature reports for deceased donor liver transplantation (DDLT) [7].

While in 2015 Gad et al. showed that the overall mortality was 75 (44.9%). The incidence of in hospital mortality was 28.7% and its most frequent cause was SFSS (6%), while the incidence of
Late mortality was 16.2% and its most frequent cause was sepsis (7.2%). On the other hand, the overall 6-months, 1-, 3-, 5- and 7-year survival of our patients were 109 (65.3%), 102 (61.1%), 95 (56.9%), 94 (56.3%) and 92 (55.1%) respectively [8].

**Complications**

The study done in National liver institute Menoufya in 2015 showed that the overall post-operative complication rate was 86.2%, and this high rate occurred due to including all types of complications (single, multiple, minor, major, complications treated medically, by intervention endoscopy, radiology and that treated surgically).

There was a trend towards significant mortality among biliary complicated cases which reached 43.7%. While vascular problems such as thrombosis and stenosis of the hepatic artery, portal vein, and hepatic vein were 21.6%. Small for size syndrome was the most frequent cause of in hospital mortality with incidence of 12.6% the second was sepsis 4.3%. Other complications like renal impairment with incidence of 21%, neurological problems in 26.3% did not affect survival.

Acute rejection which is a common cause of graft failure was 19.2%. The higher incidence of acute rejection in our study occurred due to adjusting the immunosuppressant dose to their lower limit for fear of neurotoxicity and nephrotoxicity and to avoid the occurrence of sepsis. HCV recurrence 19.2% in our study. This low incidence was due to putting strict criteria for detecting HCV recurrence, these are the biochemical, serological and histological evidences of recurrence, so we did not mention that HCV recurrence occurred until the patient fulfill all the previous parameters [8].

**Conclusion**

LDLT is successfully done in Egypt with similar results worldwide. We hope this success encourages the start of a solid deceased program to cope with the patient needs.

**References**